NRAS mutations activate downstream kinases including RAF and MEK1/2 (MAP2K1/2) [17], and preclinical and early clinical data showed that NRAS-mutant cell lines and tumors of cancer patients are highly sensitive to MEK1/2 inhibitors [13, 23]. This evidence concerns the gene MAP2K1 and cancer.